Oruka Therapeutics officer proposes $3.16M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. (ORKA) officer Arjun Agarwal gave notice of a proposed sale of 29,458 common shares, with an aggregate market value of $3,157,013.86; the approximate sale date is November 12, 2026.
Agarwal stated the shares were and will be received upon exercise of stock options over the next three months, and that acquisition and payment dates were and will be the exercise/sale dates. The notice gives February 11, 2026 as the Rule 10b5-1 plan adoption or instruction date.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Exercise of Stock Options financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.